Opioid Use Disorder and Pain

Opioid Use Disorder (OUD) is a chronic condition with exceptionally high relapse rates. Over 80% of patients receiving treatment relapse within a year. To understand the etiological processes of OUD, investigators have focused on reward seeking as a primary drinking motive. However, whereas reward and sensation seeking may be central to the early stages of OUD, it is posited that drinking as an avoidance coping behavior plays a more critical role in the maintenance of OUD. Specifically, as opioid escalates, consumption is increasingly driven by individuals' enhanced sensitivity to the aversive consequences of withdrawal. This indicates a fundamental shift of motivation from positive to negative reinforcement in OUD. Paradoxically, while users seek opioid to avoid painful physical and emotional states, chronic opioid use heightens pain reactivity, which further motivates drug use as an avoidance coping strategy. Over time, this maladaptive behavior becomes progressively less amenable to cognitive control, trapping users in a spiraling cycle of drug use and distress. The investigators thus hypothesize that dysfunctional avoidance learning is a central pathophysiological process of OUD.

Avoidance learning is a product of pain reactivity and cognitive control and their underlying brain circuits. Yet, how avoidance learning and its circuit processes are compromised in individuals with OUD remains unclear. This study aims to fill this important gap in research by investigating avoidance learning deficits as a principal mechanism of OUD.

The current proposal leverages neuroimaging, physiological recordings, and clinical assessments of avoidance learning to identify a set of markers to distinguish those with OUD from healthy controls (HC), evaluate the "diagnostic" accuracy of these markers, and describe how they may predict relapse. The investigators will also examine reward learning as a contrast to differentiate its role in OUD. Avoidance and reward learning will be operationalized via a probabilistic learning go/no-go task in which participants learn to associate cues with outcomes to avoid electric shocks and optimize reward. First, the investigators will identify brain dysfunctions in avoidance and reward learning in OUD patients and establish their inter-relationships with clinical and drug use characteristics. Next, in addition to continuing recruitment, the investigators will follow up with OUD patients for 12 months to identify predictors of relapse. The investigators will also follow up with opioid regular users to determine changes in opioid use over time.

Individuals with OUD and HCs will be recruited from the Greater New Haven, Hartford, Bridgeport areas of CT. Those with OUD will be drawn by self-referral based on seeing flyers and brochures posted at treatment programs such as the Substance Abuse Treatment Unit (SATU) and the Connecticut Mental Health Center (CMHC), by advertisements of the study, or by word of mouth. HCs will be recruited from the community by flyers and advertisements or by word of mouth.

Ninety treatment-seeking individuals with OUD (45 women) between 21 and 60 years of age and meeting the diagnosis of moderate to severe OUD will be recruited to participate in the study.

Forty individuals with regular opioid use (i.e., at least weekly, non-prescription) (20 women) aged between 21-60 who are not seeking treatment will also be recruited.

Ninety HCs (45 women) with matching demographics (including age, sex, race, and education) will be recruited. HCs will undergo the same intake assessments to confirm eligibility.

Patients with Opioid Use Disorder (OUD)

To be eligible for inclusion in the study, an individual must meet all of the following criteria:

• Between ages 21-60 years old.
• Able to read and write and provide written informed consent.
• Meet DSM-5 criteria for moderate to severe opioid use disorder; self-reported excessive opioid use prior to study entry and verified by urine toxicology testing; seeking treatment for their OUD.
• Physically healthy with no major medical illnesses, history of head injury or any neurological illness
• No plans to relocate out of state in the next 12 months (for follow-up purposes).
• Currently seeking treatment or currently receiving treatment for OUD.
• Speak English
• Have been enrolled in an inpatient or outpatient treatment program for OUD for at least 4 weeks.

Exclusion criteria

• Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.
• History of head injury with loss of consciousness (> 30 minutes).
• Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.
• Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded. Individuals who previously worked in metal industry or with metal shavings (due to a risk of any remaining metal particles moving in the eye during the MRI).
• Pregnant or lactating women will not be recruited for the study.
• Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report).
• Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.
• No pPlans to relocate out of state in the next 12 months (for follow-up purposes).
• Still experiencing significant withdrawal symptoms.

Individuals with regular opioid use

To be eligible for inclusion in the study, an individual must meet all of the following criteria:

• Between ages 21-60 years old.
• Able to read and write and provide written informed consent.
• Use non-prescribed opioids on a weekly basis or more.
• Physically healthy with no major medical illnesses, history of head injury or any neurological illness
• No plans to relocate out of state in the next 12 months (for follow-up purposes).
• Speak English

Exclusion criteria

• Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.
• History of head injury with loss of consciousness (> 30 minutes).
• Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.
• Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.
• Pregnant or lactating women will not be recruited for the study.
• Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report).
• Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.

Individuals with regular opioid use

To be eligible for inclusion in the study, an individual must meet all of the following criteria:

• Between ages 21-60 years old.
• Able to read and write and provide written informed consent.
• Use non-prescribed opioids on a weekly basis or more.
• Physically healthy with no major medical illnesses, history of head injury or any neurological illness
• No plans to relocate out of state in the next 12 months (for follow-up purposes).
• Speak English

Exclusion criteria

• Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.
• History of head injury with loss of consciousness (> 30 minutes).
• Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.
• Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.
• Pregnant or lactating women will not be recruited for the study.
• Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report).
• Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.

Individuals with regular opioid use

To be eligible for inclusion in the study, an individual must meet all of the following criteria:

• Between ages 21-60 years old.
• Able to read and write and provide written informed consent.
• Use non-prescribed opioids on a weekly basis or more.
• Physically healthy with no major medical illnesses, history of head injury or any neurological illness
• No plans to relocate out of state in the next 12 months (for follow-up purposes).
• Speak English

Exclusion criteria

• Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.
• History of head injury with loss of consciousness (> 30 minutes).
• Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.
• Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.
• Pregnant or lactating women will not be recruited for the study.
• Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report).
• Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.

Healthy controls (HC) Inclusion Criteria

• Between ages 1821-60 years old.
• Able to read and write and provide written informed consent.
• Demographics matching OUD participants.
• Speak English

Exclusion criteria

• Meet criteria for current or history of any Axis I (except nicotine use) disorder.
• Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology. History of head injury with loss of consciousness (> 30 minutes).

• Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.

• Pregnant or lactating women will not be recruited for the study. 6. Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report).

• Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.